期刊
HUMAN GENE THERAPY
卷 32, 期 13-14, 页码 694-706出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2020.321
关键词
adeno-associated virus; engineered AAV vector; human retinal organoids
资金
- Funding Program for DZNE Helmholtz
- Funding Program for TU Dresden CRTD
- Funding Program for HGF [ExNet-007]
- Deutsche Forschungsgemeinschaft (DFG) [SPP2127, MI 1238/4-1, KA2794/5-1]
rAAV vectors are widely used in gene delivery in the retina, showing safety and efficacy in treating inherited retinal dystrophies with limitations in transduction efficiency. Novel variants with modified capsid sequences have been engineered to improve this efficiency. Testing on hiPSC-derived human retinal organoids showed promising results with AAV9.NN achieving the highest efficiency in transduction. Using human organoids provides a valuable platform for evaluating novel AAV vectors for gene therapy applications in the retina.
The most widely used vectors for gene delivery in the retina are recombinant adeno-associated virus (rAAV) vectors. They have proven to be safe and effective in retinal gene therapy studies aimed to treat inherited retinal dystrophies, although with various limitations in transduction efficiency. Novel variants with modified capsid sequences have been engineered to improve transduction and overcome limitations of naturally occurring variants. Although preclinical evaluation of rAAV vectors based on such novel capsids is mostly done in animal models, the use of human induced pluripotent stem cell (hiPSC)-derived organoids offers an accessible and abundant human testing platform for rAAV evaluation. In this study, we tested the novel capsids, AAV9.GL and AAV9.NN, for their tropism and transduction efficiency in hiPSC-derived human retinal organoids (HROs) with all major neuronal and glial cell types in a laminated structure. These variants are based on the AAV9 capsid and were engineered to display specific surface-exposed peptide sequences, previously shown to improve the retinal transduction properties in the context of AAV2. To this end, HROs were transduced with increasing concentrations of rAAV9, rAAV9.GL, or rAAV9.NN carrying a self-complementary genome with a cytomegalovirus-enhanced green fluorescent protein (eGFP) cassette and were monitored for eGFP expression. The rAAV vectors transduced HROs in a dose-dependent manner, with rAAV9.NN achieving the highest efficiency and fastest onset kinetics, leading to detectable eGFP signals in photoreceptors, some interneurons, and Muller glia already at 2 days post-transduction. The potency-enhancing effect of the NN peptide insert was replicated when using the corresponding AAV2-based version (rAAV2.NN). Taken together, we report the application of an HRO system for screening novel AAV vectors and introduce novel vector candidates with enhanced transduction efficiency for human retinal cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据